Mar 27 |
PDS Biotechnology GAAP EPS of -$1.39 beats by $0.06
|
Mar 27 |
PDS Biotech Announces Clinical Strategy Update and ReportsĀ Full Year 2023 Financial Results
|
Mar 27 |
Earnings Scheduled For March 27, 2024
|
Mar 26 |
PDS Biotechnology FY 2023 Earnings Preview
|
Mar 20 |
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results
|
Mar 13 |
The 3 Most Undervalued Biotech Stocks to Buy in March 2024
|
Mar 13 |
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for InfectimuneĀ®
|
Jan 26 |
PDS Biotechnology: Advancement Of PDS0101 Continues With Expansion Data
|
Jan 23 |
PDS Biotech names Kirk V. Shepard as Chief Medical Officer
|
Jan 22 |
PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer
|